Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Rescue Therapy Using Rituximab for Multiple Sclerosis.
Saccadic intrusions: review and update.
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
In vivo gene expression revealed by cDNA arrays: the pattern in relapsing-remitting multiple sclerosis patients compared with normal subjects.
Microglia activation is associated with IFN-α induced depressive-like behavior.
Monoclonal antibodies conjugated with superparamagnetic iron oxide particles allow magnetic resonance imaging detection of lymphocytes in the mouse brain.
The Stigma Scale for Chronic Illnesses 8-Item Version (SSCI-8): Development, Validation and Use Across Neurological Conditions.
Glatiramer acetate does not protect from acute ischemic stroke in mice.
Safety issue puts daclizumab in doubt for MS
Does interferon Beta-1a impact pure-tone hearing sensitivity among individuals with multiple sclerosis?
Circulating monocytes are reduced by sphingosine-1-phosphate receptor modulators independently of S1P3.
Reactive astrocytes form scar-like perivascular barriers to leukocytes during adaptive immune inflammation of the CNS.
Modeling probability of additional cases of natalizumab-associated JCV sero-negative progressive multifocal leukoencephalopathy.
Genzyme's Lemtrada resubmission accepted for review by FDA
The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-α
Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.
Food and Drug Administration Approval Letter for Alemtuzumab
Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship.
Sanofi withdraws Campath in US and EU
The history of the oxazaphosphorine cytostatics.
Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain.
Molecular properties of epithelial, amiloride-blockable Na+ channels.
Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain.
Mitochondrial approaches for neuroprotection.
Effects of idebenone (CV-2619) and its metabolites on respiratory activity and lipid peroxidation in brain mitochondria from rats and dogs.

Pages